The global hemophilia treatment market, by Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), by Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 9,412.1 million in 2017 and is projected to exhibit a CAGR of 4.2% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights. The Hemophilia treatment market is expected to gain significant traction, owing to increasing application of gene therapy and rising R&D investments by industry players.
Gene therapy used for the treatment of hemophilia is expected to drive growth of the global hemophilia treatment market
Increasing application of gene therapy for Hemophilia treatment is expected to fuel growth of Hemophilia treatment market. For example, BMN270 (BioMarin) study in Phase 1/2 open-label testing in hemophilia A patients with very low amounts of clotting Factor VIII showed that, after a year, Factor VIII levels reaches to the healthy range. The company is expected to pass the gene therapy for hemophilia in market by 2019. In 2017, Pfizer Inc. and Spark Therapeutics Inc. also showed positive Phase 1/2 result for hemophilia B gene therapy SPK-9001. Shire Plc, UniQure N.V. and Sangamo Therapeutics Inc. also have gene therapies in pipeline.
Browse 22 Market Data Tables and 25 Figures spread through 165 Pages and in-depth TOC on “Hemophilia Treatment Market”- by Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), by Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),-Global Forecast to 2026
To know the latest trends and insights prevalent in the hemophilia treatment market, click the link below:
Major industry players are focused on strategic collaborations and acquisition to increase their market share. For instance, in 2016, Shire announced strategic merge with Baxalta to become the leading hemophilia therapy company. Baxalta is now an indirect wholly-owned subsidiary of Shire and is offering products in its specialty areas of oncology, immunology, and hematology. The key players are also focusing towards research activities, product approval, and launches to accelerate business growth. Many long lasting hemophilia treatments such as recombinant antihemophilic factor drugs Kovaltry and Eloctate, have previously showed significant returns. In 2016, Bayer AG reported US$1.44 billion sales of Kovaltry and Bioverativ Inc.’s Eloctate generated US$ 186 million in the third quarter of 2017. In 2015, the company has invested US$ 100 million in R&D, for a new testing facility at California to support work in developing new treatments for Hemophilia. Novo Nordisk generates around 10% of total revenues from Hemophilia therapy segment. It’s Hemophilia A therapy N8-GP is under Phase 3 trials and once-a-week drug N9 GP for Hemophilia B is awaiting FDA approval. CSL Behring LLC also have a strong market presence with Idelvion and Afstyla for treating Hemophilia B and A respectively.
Click Here to Buy this Report Now
Key Takeaways of the Hemophilia Treatment Market:
- The global hemophilia treatment market is anticipated to exhibit a CAGR of 4.2% over the forecast period, owing to the increasing product demand with rising patient volume.
- Among product type, recombinant coagulation factors segment holds a dominant position in the Hemophilia treatment market, owing to increasing preference by doctors and low blood related risks.
- Among disease type, Hemophilia A segment holds a dominant position in the Hemophilia treatment market, due to rising prevalence of the disease and increasing demand for prophylactic treatment.
- Key players operating in the global hemophilia treatment market include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Address:1001 4th Ave, #3200
Country: United States